Glenmark Pharmaceuticals (NSE:GLENMARK) Interest Expense : ₹-4,775 Mil (TTM As of Dec. 2023)

View and export this data going back to 2000. Start your Free Trial

What is Glenmark Pharmaceuticals Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Glenmark Pharmaceuticals's interest expense for the three months ended in Dec. 2023 was ₹ -1,343 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was ₹-4,775 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Glenmark Pharmaceuticals's Operating Income for the three months ended in Dec. 2023 was ₹ -3,557 Mil. Glenmark Pharmaceuticals's Interest Expense for the three months ended in Dec. 2023 was ₹ -1,343 Mil. Glenmark Pharmaceuticals did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Glenmark Pharmaceuticals Interest Expense Historical Data

The historical data trend for Glenmark Pharmaceuticals's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Glenmark Pharmaceuticals Interest Expense Chart

Glenmark Pharmaceuticals Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Interest Expense

Get a 7-Day Free Trial

-3,345.85

-3,773.18

-3,531.13

-2,980.99

-3,495.83

Glenmark Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Expense	Get a 7-Day Free Trial															-971.06	-1,096.84	-1,120.04	-1,214.58	-1,343.44

Glenmark Pharmaceuticals Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹-4,775 Mil.

Glenmark Pharmaceuticals (NSE:GLENMARK) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Glenmark Pharmaceuticals's Interest Expense for the three months ended in Dec. 2023 was ₹-1,343 Mil. Its Operating Income for the three months ended in Dec. 2023 was ₹-3,557 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was ₹0 Mil.

Glenmark Pharmaceuticals's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Glenmark Pharmaceuticals did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Glenmark Pharmaceuticals (NSE:GLENMARK) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Glenmark Pharmaceuticals Ltd (NSE:GLENMARK) » Definitions » Interest Expense

Traded in Other Exchanges

532296:India

Address

Glenmark House, B. D. Sawant Marg, Chakala, Off Western Express Highway, Andheri (East), Mumbai, IND, 400099

Website

https://www.glenmarkpharma.com

Glenmark Pharmaceuticals Ltd is a specialty and generic drug manufacturing company. The company's research and development activity is focused on generating intellectual property assets that will help address unmet medical needs. Glenmark's product categories include novel molecular entities, formulations, and API products. The company considers merger and acquisition investment to be a potential component for expanding its research, development, manufacturing, and marketing capabilities.

Glenmark Pharmaceuticals (NSE:GLENMARK) Headlines

No Headlines